Epstein-Barr virus latent membrane protein 1 is not associated with vessel density nor with hypoxia inducible factor 1 alpha expression in nasopharyngeal carcinoma tissue

Head and Neck Pathology

Volumn 3, Issue 4, 2009, Pages 276-282

  Benders, Alexander A ^a,b   Tang, Weihua ^a   Middeldorp, Jaap M ^b   Greijer, Astrid E ^b   Thorne, Leigh B ^a   Funkhouser, William K ^a   Rathmell, W Kimryn ^c   Gulley, Margaret L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Angiogenesis; HIF 1 ; Immunohistochemistry; Nasopharyngeal carcinoma

Indexed keywords

EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIX PROTEIN;

ARTICLE; BIOSYNTHESIS; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; NASOPHARYNX TUMOR; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VIROLOGY;

FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; NASOPHARYNGEAL NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VIRAL MATRIX PROTEINS;

EID: 72249121041     PISSN: 1936055X     EISSN: 19360568     Source Type: Journal    
DOI: 10.1007/s12105-009-0148-8     Document Type: Article

References (34)

1. Delongchamps NB, Peyromaure M. The role of vascular endothelial growth factor in kidney and prostate cancer. Can J Urol. 2007; 14(5): 3669-77.
2. Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med. 2002; 8(3): 225-32.
3. Gulley ML, Tang W. Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn. 2008; 10(4): 279-92.
4. Raab-Traub N, Flynn K, Pearson G, et al. The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. Int J Cancer. 1987; 39(1): 25-9.
5. Guang-Wu H, Sunagawa M, Jie-En L, et al. The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma. Laryngoscope. 2000; 110(12): 2066-9.
6. Khabir A, Karray H, Rodriguez S, et al. EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas. Virol J. 2005; 2: 39.
7. Kwok Fung Lo A, Liu Y, Wang X, et al. Identification of downstream target genes of latent membrane protein 1 in nasopharyngeal carcinoma cells by suppression subtractive hybridization. Biochim Biophys Acta. 2001; 1520(2): 131-40.
8. Brahimi-Horn C, Pouyssegur J. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer. 2006; 93(8): E73-80.
9. Hui EP, Chan AT, Pezzella F, et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res. 2002; 8(8): 2595-604.
10. Glaser SL, Hsu JL, Gulley ML. Epstein-Barr virus and breast cancer: state of the evidence for viral carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2004; 13(5): 688-97.
11. Vleugel MM, Greijer AE, Shvarts A, et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol. 2005; 58(2): 172-7.
12. Hatzivassiliou E, Mosialos G. Cellular signaling pathways engaged by the Epstein-Barr virus transforming protein LMP1. Front Biosci. 2002; 7: d319-29.
13. Zheng H, Li LL, Hu DS, et al. Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell Mol Immunol. 2007; 4(3): 185-96.
14. Wakisaka N, Kondo S, Yoshizaki T, et al. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha. Mol Cell Biol. 2004; 24(12): 5223-34.
15. Kondo S, Seo SY, Yoshizaki T, et al. EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1alpha through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells. Cancer Res. 2006; 66(20): 9870-7.
16. Stevens SJ, Verkuijlen SA, Hariwiyanto B, et al. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA. Int J Cancer. 2006; 119(3): 608-14.
17. Rathmell WK, Hickey MM, Bezman NA, et al. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Cancer Res. 2004; 64(23): 8595-603.
18. Greijer AE, van der Groep P, Kemming D, et al. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol. 2005; 206(3): 291-304.
19. Gordan JD, Bertout JA, Hu CJ, et al. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell. 2007; 11(4): 335-47.
20. Cosmopoulos K, Pegtel M, Hawkins J, et al. Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. J Virol. 2009; 83(5): 2357-67.
21. Lo AK, To KF, Lo KW, et al. Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci USA. 2007; 104(41): 16164-9.
22. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 2003; 22(33): 5108-21.
23. Zhong H, Semenza GL, Simons JW, et al. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev. 2004; 28(2): 88-93.
24. Cheung FM, Pang SW, Yau TK, et al. Nasopharyngeal intraepithelial lesion: latent Epstein-Barr virus infection with malignant potential. Histopathology. 2004; 45(2): 171-9.
25. Ren Q, Sato H, Murono S, et al. Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line. Laryngoscope. 2004; 114(5): 855-9.
26. Tan EL, Sam CK. Biological properties of TW01 cells expressing latent membrane protein-1 gene of EBV-derived from nasopharyngeal carcinoma cells at different stages of malignancy. Exp Oncol. 2007; 29(3): 166-74.
27. Liebowitz D. Nasopharyngeal carcinoma: the Epstein-Barr virus association. Semin Oncol. 1994; 21(3): 376-81.
28. Niedobitek G, Young LS, Sam CK, et al. Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. Am J Pathol. 1992; 140(4): 879-87.
29. Taheri-Kadkhoda Z, Magnusson B, Svensson M, et al. Expression modes and clinical manifestations of latent membrane protein 1, Ki-67, cyclin-B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma. Head Neck. 2009; 31(4): 482-92.
30. McCabe A, Dolled-Filhart M, Camp RL, et al. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst. 2005; 97(24): 1808-15.
31. Rubin MA, Zerkowski MP, Camp RL, et al. Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol. 2004; 164(3): 831-40.
32. Sullivan CA, Ghosh S, Ocal IT, et al. Microvessel area using automated image analysis is reproducible and is associated with prognosis in breast cancer. Hum Pathol. 2009; 40(2): 156-65.
33. Hoogsteen IJ, Marres HA, Bussink J, et al. Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review. Head Neck. 2007; 29(6): 591-604.
34. Jonathan RA, Wijffels KI, Peeters W, et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol. 2006; 79(3): 288-97.